Although cannabis and all its parts are considered in Israel as dangerous drugs, government support for cannabis start-ups and liberal policies with regard to research have helped the country to develop an active cannabis industry.

The domestic Israeli CBD market remains restricted, but the country can contribute to the global CBD sector in other ways, such as research and farming, according to Saul Kaye, CEO of cannabis technology and medical research firm ICann.

Currently, cannabis and its derivatives are only available through prescription. And while the law has allowed doctors to prescribe it for patients, it hasn’t allowed the market to flourish yet across the board. Overall CBD, is still considered to be like THC.

“That will ideally change,” Kaye told CBD-Intel. “We are hoping for new legislation around CBD so it will be regulated completely separately.”

Read full article
I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization